|
Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study. |
| |
|
Employment - MD Anderson Cancer Center |
|
Consulting or Advisory Role - Abbvie; Aplastic Anemia and MDS International Foundation; Aptitude Health; Astellas Pharma; Blueprint Medicines; Bristol-Myers Squibb; CancerNet; CareDx; Celgene; Cimeio Therapeutics; Clearview Healthcare Partners; CTI BioPharma Corp; Curio Science; Dava Oncology; EUSA Pharma; Harborside Press; Imedex; Immunogen; Intellisphere; Intellisphere; Magdalen Medical Publishing; Medscape; Menarini Group; Neopharm; Novartis; OncLive; Pacylex; Patient Power; Peerview; Pharmaessentia; Physicans' Education Resource |
Research Funding - US DOD (Inst) |
Other Relationship - Karger Publishers |
(OPTIONAL) Uncompensated Relationships - Dan's House of Hope; Oncology Times |
| |
|
Employment - University of Bologna, Bologna, Italy |
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; ImmunoGen; Janssen; Menarini Group; Pfizer; Ryvu Therapeutics; SERVIER; Syros Pharmaceuticals; Takeda |
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; ImmunoGen; Janssen; Menarini Group; Pfizer; Ryvu Therapeutics; SERVIER; Syros Pharmaceuticals; Takeda |
Speakers' Bureau - Abbvie; Astellas Pharma; AstraZeneca; ImmunoGen; Janssen; Menarini Group; Pfizer; Ryvu Therapeutics; Syros Pharmaceuticals; Takeda |
Research Funding - Abbvie; AstraZeneca; Daiichi Sankyo; Jazz Pharmaceuticals; MEI Pharma; Pfizer |
Travel, Accommodations, Expenses - Jazz Pharmaceuticals; Kura Oncology |
| |
|
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Jazz Pharmaceuticals; Otsuka; Pfizer; SERVIER |
Speakers' Bureau - Celgene; Daiichi Sankyo; Otsuka |
Research Funding - Abbvie (Inst); Celgene (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen-Cilag (Inst); Pfizer (Inst); Servier (Inst) |
Travel, Accommodations, Expenses - Amgen |
| |
|
Stock and Other Ownership Interests - Stelexis BioSciences, Inc. |
Consulting or Advisory Role - Cimeio Therapeutics; IDRx; Jnana Therapeutics; ProteinQure; Qiagen |
Research Funding - Abbvie; Stemline Therapeutics |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; AvenCell; Bluebird Bio; Bristol-Myers Squibb; Dark Blue Therapeutics; Debiopharm Group; Geron; Johnson & Johnson/Janssen; Molecular Partners; Novartis; Servier; Shattuck Labs; Syndax; Syros Pharmaceuticals; Taiho Oncology |
Speakers' Bureau - Incyte |
Research Funding - Aprea Therapeutics (Inst); Jazz Pharmaceuticals |
| |
|
Consulting or Advisory Role - ADC Therapeutics; Autolus; Bristol-Myers Squibb/Celgene/Juno; Genentech; Kura Oncology; Stemline Therapeutics |
Research Funding - Immunogen; Kite, a Gilead company |
Travel, Accommodations, Expenses - Miltenyi Biotec |
| |
|
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson |
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Autolus Therapeutics; Bristol-Myers Squibb/Celgene; Celgene; Incyte; Jazz Pharmaceuticals; Novartis; Ono Pharmaceutical; Rigel |
Speakers' Bureau - Abbvie; Agios; Amgen; Astellas Pharma; Blueprint Medicines; Bristol-Myers Squibb; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Rigel; Sanofi; Seattle Genetics/Astellas; Stemline Therapeutics |
Research Funding - Abbvie; Actinium Pharmaceuticals; Actuate Therapeutics; Agios; Amgen; Aptevo Therapeutics; Arog; Astellas Pharma; AVM Biotechnology; Bio-Path Holdings; Biomea Fusion; Biosight; Bristol-Myers Squibb/Celgene; Celator; Cellectis; Celularity; Cogent Biosciences; Constellation Pharmaceuticals; Cullinan Oncology; Daiichi Sankyo; Deciphera; Delta-Fly Pharma; ElevateBio; Fate therapuetics; FORMA Therapeutics; Fujifilm; Gamida Cell; Genentech/Roche; Geron; glycomimetics; Immune-Onc Therapeutics; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Kronos Bio; Kura Oncology; Loxo; Marker Therapeutics; Mateon Therapeutics; Novartis; Onconova Therapeutics; Ono Pharmaceutical; Pfizer; PrECOG; REGiMMUNE; REGiMMUNE; Samus Therapeutics; Sangamo Bioscience; Sanofi; Sellas Life Sciences; Stemline Therapeutics; Syros Pharmaceuticals; Syros Pharmaceuticals; Takeda; Tolero Pharmaceuticals; Trovagene |
| |
|
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; Bristol-Myers Squibb/Celgene; Celgene; Daiichi Sankyo; Glycomimetics; Immunogen; Incyte; Janssen Oncology; Jazz Pharmaceuticals; Kura Oncology; Macrogenics; Novartis; Pfizer; Schrodinger; SERVIER; Stemline Therapeutics; Sumitomo Dainippon Pharma Oncology; Takeda; Trillium Therapeutics |
Speakers' Bureau - Abbvie; Agios; Bristol Myers Squibb Foundation; Incyte; Jazz Pharmaceuticals; Novartis; SERVIER; Syndax |
Research Funding - Abbvie (Inst); Abbvie (Inst); Agios (Inst); ALX Oncology (Inst); Amgen (Inst); Aptose Biosciences (Inst); Ascentage Pharma (Inst); Daiichi Sankyo (Inst); FORMA Therapeutics (Inst); Gilead/Forty Seven (Inst); Glycomimetics (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Macrogenics (Inst); Novartis (Inst); Oryzon Genomics (Inst); PTC Therapeutics (Inst); SERVIER (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst) |
Other Relationship - Bristol-Myers Squibb/Celgene; Celgene; Glycomimetics |
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo |
| |
|
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Celgene/Bristol-Myers Squibb; CTI BioPharma Corp; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Immunogen; Johnson & Johnson/Janssen; Kite/Gilead; Kura Oncology; Novartis; Qiagen; Rigel; Ryvu Therapeutics; Schrodinger; SERVIER; Stemline Therapeutics; Sumitomo Pharma Oncology; Syndax; Takeda |
Speakers' Bureau - Astellas Pharma; Daiichi Sankyo/UCB Japan; DAVA Pharmaceuticals; Pfizer |
Other Relationship - Abbvie/Genentech; Gilead Sciences; Gilead Sciences; UpToDate |
| |
|
Consulting or Advisory Role - Abbvie; Adicet Bio; BerGenBio; Bristol-Myers Squibb/Celgene/Juno; GlaxoSmithKline; Kura Oncology; Orum Therapeutics; WUGEN, Inc. |
Research Funding - Amgen (Inst); Aptevo Therapeutics (Inst); Immunogen (Inst); Janssen Research & Development (Inst); Jazz Pharmaceuticals (Inst); Kite/Gilead; Kura Oncology (Inst); Macrogenics (Inst); Pfizer; Vor Biopharma (Inst) |
| |
|
Consulting or Advisory Role - Stemline Therapeutics |
Research Funding - Abbvie (Inst); ImmunoGen (Inst); Janssen (Inst); Novartis/Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Grifols; ImmunoGen; Janssen-Cilag; Novartis/Pfizer; Stemline Therapeutics |
| |
|
Consulting or Advisory Role - Seagen; Seagen |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - University of Bologna, Bologna, Italy |
| |
|
Consulting or Advisory Role - Amgen; Blueprint Medicines; Gilead Sciences; Incyte; Jazz Pharmaceuticals; Novartis; Pfizer; servier; takeda |
Research Funding - Abbvie (Inst); Blueprint Medicines (Inst); glycomimetics (Inst); Novartis (Inst) |
| |
|
|
Stock and Other Ownership Interests - Abbvie |
| |
|
No Relationships to Disclose |
| |
|
Employment - MD Anderson Cancer Center |
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Kite, a Gilead company; Menarini; Novartis; Pfizer; SERVIER; Shattuck Labs; Syndax; Trillium Therapeutics |
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); FATE Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immunogen (Inst); Kite, a Gilead company (Inst); Novimmune (Inst); Pfizer (Inst); Servier (Inst); Trillium Therapeutics (Inst); Trovagene (Inst) |